Sitagliptin (100 mg) + Metformin Hydrochloride (500 mg) SR + Pioglitazone (15 mg) is a triple oral antidiabetic combination used for the effective management of Type 2 Diabetes Mellitus. This formulation works through three complementary mechanisms to achieve optimal glycemic control. Sitagliptin, a DPP-4 inhibitor, enhances incretin hormones, thereby increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner. Metformin SR, a biguanide, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity while offering sustained release for prolonged action and better gastrointestinal tolerability. Pioglitazone, a thiazolidinedione, enhances insulin sensitivity in adipose tissue, skeletal muscle, and the liver by activating PPAR-? receptors. Together, this combination provides improved fasting and postprandial blood glucose control, reduces insulin resistance, and helps in long-term HbA1c reduction in patients inadequately controlled with dual therapy.